Ulcerative colitis

This study tests a daily medication called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (no active symptoms) by week 10 or 22. Participants take the pill once daily and…

This early-stage trial is testing a drug called vixarelimab in 24 people with moderate to severe ulcerative colitis who have not improved with standard treatments. The study looks at how the drug affects the gut, how it moves through the body, and whether it is safe. It is too ea…

This study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some …

This study tests whether dupilumab can help people with moderate to severe ulcerative colitis that has a certain type of immune cell activity (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks. The main goal is to see if symptoms and…

This Phase 3 trial tests whether the drug Afimkibart can help people with moderate-to-severe ulcerative colitis achieve remission. About 400 adults who have not responded well to other treatments will receive either Afimkibart or a placebo. The study measures remission at 12 and …

This study tests an oral medication called tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and bleeding. The goal is to see if the drug can bring the disease into remission (no symptoms and healed gut l…

This study tests whether giving vedolizumab every 4 weeks instead of every 8 weeks can help Japanese patients with moderate to severe ulcerative colitis or Crohn's disease whose symptoms returned during standard treatment. About 56 participants will receive the drug intravenously…

This study looks at whether taking a common ulcerative colitis medication (5-ASA) at a specific time of day—morning or evening—can better reduce hidden inflammation. Thirty-two adults with inactive UC will try both timing schedules over three months. Researchers will measure infl…

This study tests an injected drug called guselkumab for people with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. About 418 adults who haven't responded well to other treatments will receive either the…

This study tests a drug called golimumab in children aged 2-17 with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (symptom relief) within 6 week…

This study tests whether combining two biologic drugs, guselkumab and golimumab, works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 participants who haven't responded well to other advanced therapies will receive injections of the…

This study tests guselkumab, a drug that targets inflammation, in over 1,000 people with moderate to severe ulcerative colitis. Participants receive either guselkumab or a placebo to see if the drug can improve symptoms and lead to remission. The goal is to find a new treatment o…

This study follows 159 children aged 2 to 17 who have already completed a prior ustekinumab study for Crohn's disease, ulcerative colitis, or psoriatic arthritis. The goal is to collect long-term safety data by monitoring side effects, lab results, and injection-site reactions. P…

This study tests a new medicine called SHR-1139 in 21 adults with moderate-to-severe ulcerative colitis, a condition that causes inflammation in the colon. The treatment has two parts: 12 weeks of induction therapy followed by 48 weeks of maintenance therapy. The main goal is to …

This study tests a drug called guselkumab in children aged 2-17 with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. The goal is to see if the drug can bring the disease under control and keep it in remission for up to 56 weeks. About 112 chi…

This study compares two approved drugs, risankizumab and vedolizumab, in about 530 adults with moderate to severe ulcerative colitis who have not tried targeted therapies before. Participants will receive one of the two drugs for about a year. The main goal is to see which drug b…

This study tests whether vedolizumab, given as an IV infusion, can help Chinese adults with moderate to severe ulcerative colitis. About 392 participants will receive either the drug or a placebo. The goal is to see if it reduces symptoms like diarrhea and bleeding, and helps ach…

This study looks at the long-term safety and effectiveness of balinatunfib, an oral tablet, in adults with Crohn's disease or ulcerative colitis. Participants have already completed a one-year treatment in a previous study. The trial will last up to 107 weeks and includes both do…

This study looks at the long-term safety of filgotinib, a drug for ulcerative colitis, in over 1,100 adults who already took part in a filgotinib trial. The main goal is to track side effects and lab test changes over time. Participants must have completed a prior filgotinib stud…

This study tests two different doses of TEV-48574 (duvakitug) given as a shot every 4 weeks to adults with moderate to severe ulcerative colitis or Crohn's disease. Participants who completed a previous 14-week study can join. The goal is to see if the drug can keep the disease u…

This study tests an oral medication called upadacitinib in children aged 2 to 17 with moderate-to-severe ulcerative colitis who have not improved with standard treatments. The goal is to see if the drug can reduce inflammation and control symptoms like diarrhea and bleeding. Part…

This study looks at the long-term safety and effectiveness of the drug etrasimod for people with moderate to severe ulcerative colitis. Participants had already taken part in earlier studies and will continue taking etrasimod for up to 2 years. The goal is to see if the drug can …

This Phase 2a trial is testing an injectable biologic drug called ALTB-268 in 50 adults with moderately to severely active ulcerative colitis that has not improved with other biologic therapies. The study is open-label, meaning everyone receives the drug, and will measure changes…

This study tests an oral drug called TAK-279 (Zasocitinib) in 207 adults with moderate-to-severe ulcerative colitis. Participants take either the drug or a placebo for 12 weeks, then everyone gets the drug for up to a year. The goal is to see if TAK-279 reduces bowel inflammation…

This study looks at whether using just one medication (infliximab) under the skin works as well as using it together with another immune-suppressing drug for people with Crohn's disease or ulcerative colitis. About 420 adults who have already started infliximab will be followed f…

This early-stage trial tests a new drug called ALTB-268, a monoclonal antibody, in 24 healthy volunteers. The main goal is to check safety and how the body processes the drug. If it passes safety checks, it may later be tested in people with ulcerative colitis to see if it can co…

This study tests the long-term safety and effectiveness of an experimental drug called ABX464 in people with moderate to severe ulcerative colitis. Participants who previously improved on ABX464 in earlier studies will continue taking it daily for up to 54 months. Researchers wil…

This study tests whether adding high-dose vitamin D3 to standard anti-TNF therapy can improve symptoms and reduce inflammation in people with active Crohn's disease or ulcerative colitis. About 100 adults starting anti-TNF treatment will receive either vitamin D3 or a placebo for…

This Phase 2 trial tests an oral drug called SAR443122 in 187 adults with moderate to severe ulcerative colitis who haven't responded well to other treatments. Participants receive either the drug or a placebo for up to 52 weeks. The goal is to see if the drug can safely help ach…

This study tests a support program for teens aged 16-17.5 with Crohn's disease or ulcerative colitis as they move from pediatric to adult healthcare. The program includes personalized assessments, a transition navigator, and virtual skill-building sessions. Researchers will measu…

This study looks at whether the probiotic VSL#3 can change how bile acids work in people with Crohn's disease or ulcerative colitis. About 79 participants will take two sachets of VSL#3 daily for six weeks. Researchers will measure bile acid levels in blood and stool to see if th…

This study looks at how well and how safely the drug mirikizumab works over the long term (up to 3 years) for people with moderate to severe ulcerative colitis. About 1,058 adults who were already in earlier studies will continue treatment. The goal is to see if the drug can keep…

This study aimed to test whether injecting stem cells from a donor's bone marrow into the pouch (a surgically created internal reservoir) could safely treat pouchitis that hadn't improved with antibiotics or other drugs. The trial was planned for 12 adults aged 18-75 in the U.S.,…

This study tests whether a fecal transplant (FMT) can safely and effectively treat recurrent C. difficile infections in children, including those with inflammatory bowel disease (IBD). Researchers will give FMT to 250 children aged 3-21 and track whether the infection comes back.…

This study tests an experimental drug called emvistegrast (GS-1427) in about 228 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo, and researchers check if symptoms improve after 12 weeks. The goal is to see if the drug can redu…

This early-stage trial is testing a new drug called GSK4528287 for the first time in humans. The goal is to check for side effects and see how the drug behaves in the body. 48 healthy volunteers will receive a single dose, with the amount increased gradually in different groups. …

This study tests a new drug called Hemay005 for people with moderate to severe ulcerative colitis, a chronic gut condition. About 92 participants will receive either a low dose, high dose, or a placebo for 12 weeks. The goal is to see if the drug can reduce symptoms like diarrhea…

This phase 3 trial tests a drug called tulisokibart (MK-7240) in about 1,020 people with moderate-to-severe ulcerative colitis. The drug is a lab-made antibody given by IV or injection. The goal is to see if it can help people achieve and maintain remission (fewer symptoms and le…

This study tests whether using a computer dashboard to guide infliximab dosing is more effective and safer than standard dosing for people with Crohn's disease or ulcerative colitis. About 124 participants will receive either dashboard-guided or standard treatment, with the goal …

This study tests a digital health system that reminds people with inflammatory bowel disease (IBD) to take their medication and lets them report symptoms. About 123 adults starting a new oral or injectable treatment will use the system or get standard care for 12 months. The goal…

This pilot study tests whether a plant-based resistant starch, tailored to each child's gut bacteria, can improve gut health in 80 children with Crohn's disease or ulcerative colitis. Participants will take the starch or a placebo for a period, and researchers will measure change…

This study tests whether a plant-based starch, tailored to each child's needs, can help restore a healthier gut microbiome in children with inflammatory bowel disease (Crohn's or colitis). About 100 children with mild disease or in remission will receive the starch for 6 months. …

This early-stage study tests whether delivering a patient's own stem cells directly into the artery that supplies the colon is safe for people with moderate to severe ulcerative colitis. Twenty adults who have not responded to at least two standard treatments will receive one dos…

This phase 2 trial tests Aquamin, a mineral supplement made from red marine algae, in 40 people with mild ulcerative colitis or those in remission. Researchers want to see if it improves symptoms, reduces inflammation, and helps maintain remission. Participants take 4 capsules da…

This phase 3 study tests whether risankizumab, an injected drug, can safely maintain remission in people with ulcerative colitis who already improved with the same drug. Over 1,200 participants will receive either risankizumab or a placebo for 52 weeks, with an option to continue…

This study tests whether transplanting healthy donor stool into the gut can help people with ulcerative colitis, a chronic bowel disease. About 150 adults with active or steroid-dependent disease will receive either real fecal transplants or a sham procedure. The goal is to see i…

This study tests whether MitoQ, a supplement that protects cell batteries (mitochondria), can help people with moderate ulcerative colitis (UC) flare-ups. About 79 adults will take either MitoQ or a placebo daily for 24 weeks, alongside standard steroid treatment. The goal is to …

This study tests the long-term safety and effectiveness of upadacitinib (RINVOQ) in about 950 people with ulcerative colitis who didn't respond well to earlier treatment. Participants take the drug or a placebo orally. The goal is to see if it can control the disease over time wi…

This study tests a specially selected probiotic (LR607) in 300 people with mild-to-moderate ulcerative colitis, a form of inflammatory bowel disease. The probiotic is designed to boost a natural gut pathway (NOD2) that helps control inflammation. The goal is to see if adding LR60…

This study looks at whether a gluten-free diet can help people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). Researchers will track changes in symptoms, gut bacteria, and lab results in 60 adults over time. The goal is to see if avoiding gluten c…

This study aimed to test whether MitoQ, a dietary supplement with antioxidant properties, could help control inflammation in children aged 6–17 with mild-to-moderate ulcerative colitis. Participants would have taken MitoQ or a placebo daily for 24 weeks alongside their usual medi…

This study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…

This study follows 509 adults with moderate to severe ulcerative colitis who are starting filgotinib, a drug also known as Jyseleca. Researchers want to see how long people stay on the treatment, how well it controls symptoms, and how it affects quality of life in everyday medica…

This study tests three different doses of an experimental drug called MORF-057 in 280 adults with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The goal is to see if the drug can safely help patients achieve remission, meaning less bleeding, more no…

This study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard steroid drugs helps people with severe ulcerative colitis get better faster. About 44 adults with acute severe colitis will be randomly assigned to receive eithe…

This study looks at whether adding CurQD, a mix of curcumin and QingDai, helps people with active ulcerative colitis who are already taking vedolizumab. Researchers will review records from 400 patients to see if the supplement helps them stay on vedolizumab longer and improves s…

This phase 3 trial tests whether a daily pill called ABX464 (obefazimod) can help people with moderate-to-severe ulcerative colitis stay in remission. Over 1,100 participants who completed an earlier induction study will receive either 25 mg, 50 mg, or a placebo for 44 weeks. The…

This study tests a new drug called lutikizumab in about 156 adults with moderate to severe ulcerative colitis, a condition causing inflammation and bleeding in the colon. Participants receive either lutikizumab or adalimumab (Humira) for 12 weeks, then continue based on response.…

This study tests a new drug called rosnilimab in 132 adults with moderate to severe ulcerative colitis. The goal is to see if it can reduce disease activity and improve symptoms compared to a placebo. Participants must have tried other treatments without success. The trial is act…

This study tests whether two special diets—the specific carbohydrate diet or an elemental (liquid) diet—can help people with active Crohn's disease or ulcerative colitis feel better. Forty adults will choose one diet and follow it for 6 weeks, while researchers track symptoms, in…

This early-phase study tests CP101, an oral capsule made from healthy donor stool, in 30 adults with mild-to-moderate ulcerative colitis. The goal is to see if the drug can safely restore a healthy gut microbiome and improve symptoms. Participants receive either a short or extend…

This study tests fecal microbiota transplantation (FMT) in 30 people with mild-to-moderate ulcerative colitis. Participants receive donor stool either through a colonoscopy or as capsules at weeks 0 and 4. The goal is to see if FMT can help achieve steroid-free remission and impr…

This study tests whether fecal microbiota transplant (FMT) capsules can help people with inflammatory bowel disease (IBD) who haven't improved on standard biologic drugs. 94 patients with mild-to-moderate Crohn's or ulcerative colitis will receive either FMT capsules plus a biolo…

This study checks if a new stool test can better tell the difference between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) compared to current tests. About 300 adults and teens will give a stool sample and have a colonoscopy as part of their regular care. If…

This study tests whether atorvastatin, a widely used cholesterol medication, can reduce the risk of colon cancer in people with long-standing ulcerative colitis who carry a specific genetic mutation (P53). About 42 participants will take either atorvastatin or a placebo for a per…

This study tests whether listening to jazz or reggae music can reduce chronic pain in people with IBS, Crohn's disease, or colitis. Researchers will compare two groups: one listens to mindful jazz, the other to reggae, over four weeks. The goal is to find a safe, non-addictive wa…

This study tests whether personalized exercise coaching can reduce fatigue and improve quality of life in children with inflammatory bowel disease (IBD). Seventy children will be split into two groups based on their current exercise habits and will follow a 24-week program with a…

This study looks at whether health education from nurses can improve quality of life and reduce anxiety and depression in people who have had digestive surgery and now have an ostomy. About 70 adults with permanent or long-term ostomies will take part in workshops and follow-up s…

This study looks at whether acupuncture can reduce disease activity and pain in children with mild-to-moderate Crohn's disease or ulcerative colitis. About 60 kids on stable medication will receive acupuncture alongside their usual care. Researchers will measure changes in sympto…

This study follows up to 500 people with acute or chronic inflammatory disorders, such as infections or immune problems, over time. Researchers will monitor participants with standard tests and may screen them for other studies. The goal is to better understand these conditions a…

This study looks at whether regular text message check-ins and the ability to text your IBD care team can improve disease management and quality of life. About 900 people with Crohn's disease or ulcerative colitis will take part. Some will get extra symptom surveys and texting ac…

This study looks at whether two blood markers, zonulin and LBP, can help detect liver damage in people with both ulcerative colitis (UC) and fatty liver disease. Researchers will measure these markers and use a special ultrasound to check liver stiffness in 100 adults with UC who…

This pilot study tests whether daily, at-home stimulation of a nerve in the ear can change brain activity in people with inflammatory bowel disease (IBD) who are in remission. Fifteen adults with Crohn's disease or ulcerative colitis will use a small device for 28 days and underg…

This study looks at how diet, genetics, and gut bacteria work together to cause digestive problems like IBS, IBD, and celiac disease. Researchers will follow about 4,000 adults with and without these conditions to find patterns. The goal is to understand why some people get sick …

This registry follows 535 adults with moderate-to-severe ulcerative colitis who are taking or starting Simponi. Researchers will track serious side effects like infections, cancers, and pregnancy outcomes over time. The goal is to better understand the long-term safety of this me…

This study follows nearly 5,000 children with Crohn's disease, ulcerative colitis, or indeterminate colitis to monitor the long-term safety of their treatments, including the drug infliximab. Researchers collect information on side effects, disease activity, and quality of life o…

This study looks at whether taking extra random biopsies during a colonoscopy helps find precancerous growths in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. About 1,600 participants will be randomly assigned to one of two biopsy…

This study looks at how the drug infliximab behaves in the body of people hospitalized with severe ulcerative colitis. Researchers measure drug levels in blood, stool, and colon tissue, along with changes in proteins and genes. The goal is to better understand how the drug works,…

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This study looks at how diet affects inflammation in people with Crohn's disease or ulcerative colitis (IBD). About 140 participants will either follow a Nordic-based test diet for six weeks or use a digital information tool. Researchers want to see if these approaches can reduce…

This study observes 1006 adults with ulcerative colitis or Crohn's disease in Brazil who are taking or have taken vedolizumab. Researchers will look at how long patients stay on the drug and what other treatments they used before. No new treatment is given—this is just a review o…

This study looks at 200 people with known or suspected inflammatory bowel disease (IBD). Researchers will use computers to analyze standard medical images and videos from endoscopies, biopsies, and scans. The goal is to create automated metrics that might help doctors assess IBD …

This study observes how 4,000 adults with ulcerative colitis are treated in real-world clinics, not in a controlled trial. Researchers will analyze prescription patterns and outcomes to create an updated treatment flowchart. The goal is to improve understanding of which therapies…

This study looks back at medical records of 120 adults with Crohn's disease or ulcerative colitis who switched from intravenous to subcutaneous (under-the-skin) vedolizumab. Researchers want to see what dosing patterns doctors used and whether patients achieved remission. No new …

This study is a registry that will review medical records of 1,000 patients treated for benign or malignant gastrointestinal diseases between 2005 and 2030. Researchers will look at survival, symptoms like heartburn and swallowing trouble, and quality of life. The goal is to lear…

This study is testing a special thermal probe that measures temperature changes in the lining of the colon during a routine colonoscopy. The goal is to see if the probe can detect inflammation in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerati…

This 5-year observational study is following 15,000 adults and children with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, in real-world clinics. Researchers are collecting data on disease patterns, treatment use, and patient outcomes to bett…

This study looks at whether continuous heart rate variability (HRV) monitoring can predict how well patients with inflammatory bowel disease (IBD) respond to biologic therapies like infliximab or vedolizumab. Researchers will track HRV in 100 patients starting treatment and compa…

This study aims to understand how inflammatory bowel disease (IBD) affects patients' quality of life. Researchers will survey 385 adults with Crohn's disease or ulcerative colitis about their symptoms, emotional well-being, and social support. The goal is to identify factors that…

This study follows 189 adults hospitalized with acute severe ulcerative colitis to track their treatments and outcomes. Researchers will collect detailed medical data to identify factors that predict whether a patient needs stronger medications or emergency surgery. The goal is t…

This study is collecting blood, stool, and urine samples from 1,000 people with Inflammatory Bowel Disease (IBD). Researchers will store these samples along with medical information to learn more about the disease and find ways to improve patient outcomes. The study does not invo…

This observational study is following up to 500,000 adults with chronic gastrointestinal diseases like Crohn's disease, ulcerative colitis, and eosinophilic GI disease. Researchers will collect data from electronic health records and patient reports to understand how these condit…

This study looks at 672 people with active ulcerative colitis to find the best treatment target. Participants are split into three groups: one aiming for symptom relief only, another for symptom plus endoscopic healing, and a third for symptom, endoscopic, and microscopic healing…

This long-running study at Johns Hopkins aims to identify the genetic and environmental factors that cause inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers are enrolling 2,500 participants — including patients, their family members, …

This study aims to better understand inflammatory bowel disease (IBD) by collecting tissue samples from 1,100 people undergoing endoscopy or bowel surgery. Researchers will analyze gene activity, proteins, and gut microbes to learn what causes the disease. The study includes both…

This study aims to find genes that cause inflammatory bowel disease (IBD) specifically in African Americans. Researchers will collect health information and blood samples from 2,400 African Americans, both with and without IBD. No treatment is given—the goal is to better understa…

This study observes 562 adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are starting or switching to Hyrimoz®, a biosimilar of adalimumab. Researchers will track how many patients continue the treatment after 6 months and why some stop, such as …

This registry is following over 2,200 adults with inflammatory bowel disease (IBD) across North America to see how approved treatments work in everyday practice. Researchers are collecting data on disease patterns, complications, and patient outcomes. The goal is to better unders…

This study is collecting health information from 2,000 people with Crohn's disease or ulcerative colitis across three hospitals in South Korea. Researchers aim to build computer models that can predict how each patient will respond to different treatments. No new drugs are being …